April 2008 in “Australasian journal of dermatology”
The book gives a basic overview of mesotherapy and fat-dissolving injections but lacks detailed guidance and effectiveness comparisons for practitioners.
31 citations
,
November 2009 in “European journal of dermatology/EJD. European journal of dermatology”
This paper presents a consensus-driven diagnostic evaluation form for assessing hirsutism in premenopausal women, developed by The Skin Academy for use in clinicalpractice.
This source reports that trastuzumab deruxtecan improves outcomes in HER2-positive and HER2-low metastatic breast cancer, emphasizing the need for careful adverse event monitoring, particularly for interstitial lung disease, and managing emetic risk to maximize benefits.
In this study, researchers found that while 16 out of 116 American Medical Association House of Delegates associations provide materials on healthcare for incarcerated individuals, there is a notable lack of practical clinicalguidance, which may lead to inconsistent healthcare practices for this population.
February 2026 in “Indian Dermatology Online Journal”
This study highlights that while hair oiling is an important cultural tradition in India, it may cause scalp issues for some people, suggesting a need for balanced, evidence-based dermatological advice.
Clascoterone is a topical treatment for androgenetic alopecia, showing modest to moderate hair regrowth, and may be available by 2027-2028. It is considered safer than finasteride, with discussions on its effectiveness compared to RU58841 and pyrilutamide.
Clascoterone 5% solution shows strong potential for hair growth, offering a new treatment for alopecia with minimal side effects. It blocks androgen receptors locally and may be available by late 2026 or early 2027.
Topical Clascoterone showed a 539% improvement in hair count compared to placebo, but its effectiveness and safety are debated. Users compared it to minoxidil and finasteride, with mixed opinions on its potential release in 2026 or 2027.
Switching generic finasteride manufacturers can reduce side effects while maintaining effectiveness. Different fillers in generics may affect bioavailability and cause varying side effects.
Dutasteride is generally considered more effective than finasteride for hair regrowth, with some users experiencing better results, especially at higher doses. However, individual responses vary, and some users report side effects or no response to either treatment.